Open-angle Glaucoma Clinical Trial
Official title:
Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Primary Open-angle and Normal Tension Glaucoma Patients
Verified date | September 2011 |
Source | Universitaire Ziekenhuizen Leuven |
Contact | n/a |
Is FDA regulated | No |
Health authority | Belgium: Ethics Committee |
Study type | Observational |
Color Doppler Imaging (CDI) has been providing information about ocular blood flow over the
past decades. This non-invasive procedure based on ultrasound technique has identified
increased resistance and decreased systolic blood velocities to exist in the ophthalmic
arteries of glaucoma patients. However, existing data has provided very little information
regarding the analysis of the Doppler waveform in itself and to whether variables such as
early systolic acceleration or systolic/diastolic velocity ratios are of any significance in
glaucoma disease. In other medical specialties using CDI technology, such as nephrology or
cardiology for instance, this analysis has been part of the normal routine. This information
has been used in screening patients for disturbed circulation such as arterial stenosis or
providing information regarding prognosis of renal and hepatic transplants have been used
for decades now.
What is the normal characteristics of the waveform Doppler analysis? To answer this, the
investigators will create a normative database using healthy controls.
Are there signs of altered stiffness or compliance in the ophthalmic arteries of glaucoma
patients? To answer this, the analysis of early acceleration acceleration and detection of
an early peak systolic will be done on the Doppler curves of glaucoma patients and compared
to the healthy normative database.
Are there any difference between the two types of glaucoma [primary open-angle glaucoma
(POAG) and normal-tension glaucoma (NTG)]? The investigators will compare the variables of
the ophthalmic artery waveform in these two groups.
Do any of these Doppler waveform variables have any clinical significance? To answer this,
the investigators will search for the existence of any correlation between the waveform data
and both functional (visual field testing) and structural (Confocal scanning laser
ophthalmoscopy - CSLO) variables of the glaucoma groups.
Status | Completed |
Enrollment | 150 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - • individuals over 18 years old - willing to sign an informed consent and able to comply with the requirements of the study - having no other ocular diseases besides glaucoma Exclusion Criteria: - • history of ocular trauma - intraocular surgery (except for cataract surgery) - eye disease (except glaucoma) - systemic diseases with ocular involvement like diabetes |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Belgium | Department of Ophthalmology, UZLeuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
Universitaire Ziekenhuizen Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Early Systolic Acceleration as a measure of vascular disfunction of the ophthalmic arteries in glaucoma patients | Color Doppler Imaging of the ophthalmic artery will provide the waveform of the vessel. There will be a operator-dependent identification of the slope at the beggining of the cardiac cycle and a quantification of the early systolic acceleration. This numberical data will then be compared between healthy and glaucoma groups. Such variables will further be compared to the clinical data (functional - visual field defects and structural - CSLO). | hospital stay, average 3 hours | No |
Secondary | Ratio between systolic and diastolic blood flow velocities as a measure of arterial compliance of the ophthalmic artery in glaucoma patients | Using the CDI-provided ophthalmic artery waveform, there will be an operator-dependent analysis of systolic and diastolic mean blood flow velocities. the ratio between these two variables will be calculated and the numerical data obtained will be compared between the healthy and glaucoma groups. Such ratio will furthermore be compared to functional and structural damage (visual field damage and CSLO, respectively). | Hospital stay, average 3 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01456390 -
Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents
|
N/A | |
Completed |
NCT01443988 -
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
|
Phase 4 | |
Completed |
NCT01444040 -
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
|
Phase 4 | |
Completed |
NCT01340014 -
Patient Preference Comparison of AZARGA Versus COSOPT
|
Phase 4 | |
Completed |
NCT01444105 -
Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty
|
N/A | |
Completed |
NCT01455467 -
Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery
|
N/A | |
Completed |
NCT01426867 -
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
|
Phase 2 | |
Completed |
NCT01415401 -
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
|
Phase 4 | |
Completed |
NCT00759239 -
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
|
Phase 4 | |
Completed |
NCT00397241 -
24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
|
Phase 4 | |
Completed |
NCT00918346 -
Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
|
Phase 3 | |
Completed |
NCT00273481 -
Cosopt Versus Xalacom
|
Phase 4 | |
Completed |
NCT00716742 -
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
|
N/A | |
Completed |
NCT02558400 -
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Withdrawn |
NCT03648229 -
African Glaucoma Laser Trial
|
Phase 4 | |
Completed |
NCT01978600 -
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
|
Phase 4 | |
Completed |
NCT01699464 -
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
|
Phase 2 | |
Completed |
NCT01464424 -
Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
|
Phase 4 |